Drug Profile
Crisaborole - Pfizer
Alternative Names: AN-2728; Crisaborole ointment; Eucrisa; PF-06930164; PF-06940799; STAQUISLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals; Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield
- Developer Anacor Pharmaceuticals; Duke University; Pfizer Canada; Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield
- Class Anti-inflammatories; Antipsoriatics; Benzonitrile; Heterocyclic bicyclo compounds; Nonsteroidal anti-inflammatories; Organic boron compounds; Phenyl ethers; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Phase II Circumscribed scleroderma; Vitiligo
- Suspended Psoriasis
- Discontinued Dermatitis
Most Recent Events
- 10 May 2023 Efficacy and safety data from a phase II trial in Dermatitis presented at the American Academy of Dermatology annual Meeting 2023
- 23 Sep 2022 Phase-II clinical trials in Vitiligo in USA (Topical) (NCT05298033)
- 28 Mar 2022 University of Colorado plans a phase II trial for Vitiligo (Topical, Ointment) in May 2022, (NCT05298033)